Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dutch biotechnology company Crucell NV and the biotech manufacturer DSM Biologics have jointly agreed to allow Japanese pharmaceutical company UMN Pharma to conduct research using the PERC6 cell line.
Subscribe to our email newsletter
UMN Pharma will use the PERC6 cell line in its UMN-03 project, which aims to employ a fusion protein in the treatment of muscular dystrophy and metabolic diseases such as obesity and type 2 diabetes mellitus.
In addition, Crucell and DSM Biologics will provide UMN Pharma with various services including vector construction, clone generation, process development and cGMP manufacturing.
Under the terms of the agreement, UMN Pharma will pay a signing fee and annual maintenance fees. The additional services will also attract fees. Further financial details were not disclosed.
Crucell NV is a biotechnology company focused on research, development, production and worldwide marketing of vaccines and antibodies that combat infectious diseases.